Amgen's PCSK9 contender lines up for EU nod; Medicago splashes $245M on new plant;

@FierceBiotech: ICYMI: Novo's liraglutide works in diabetes and obesity. How about NASH? More | Follow @FierceBiotech

@JohnCFierce: Got a few personal notes and saw at least 1 Twitter campaign linked to our "Influentials' list. Check out the report. Feature | Follow @JohnCFierce

> The European Medicines Agency's Committee for Medicinal Products for Human Use is slated to weigh in on Amgen's ($AMGN) cholesterol-lowering antibody evolocumab this week. Agenda

> Vaccine developer Medicago is spending $245 million to construct a new manufacturing facility in its native Quebec. News

> DNAtrix has teamed up with Alcyone Lifesciences, planning to use the company's drug delivery technology as it develops a treatment for brain cancer. More

Medical Device News

@FierceMedDev: UPDATED w/ interview: Apollo's minimally invasive intragastric weight-loss balloon shows promise in clinical trial. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Advice for med tech entrepreneurs: Identify your customer and consider stakeholders' incentives carefully. Editor's corner | Follow @VarunSaxena2

@EmilyWFierce: $ILMN filed a patent infringement suit against Ariosa/$RHHBY over prenatal testing tech. Release | Follow @EmilyWFierce

> Silk Road scores FDA approval for less invasive stent system. Story

> NEA startup ClarVista gets $14.5M to gain CE mark for intraocular lens. Article

Pharma News

@FiercePharma: J&J nears $7.5M deal in Risperdal case that could have cost $1.2B. Report | Follow @FiercePharma

@EricPFierce: FDA blesses Baxter saline plant in Spain for shipments to U.S. of 0.9% sodium chloride. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to go. Report | Follow @CarlyHFierce

> Can Baxalta deliver on its big growth promises? Baxter says yes. More

> Merck KGaA stumbles in Q1 as MS injectable Rebif falls to oral rivals. Report

> Lechleiter takes up Big Pharma's torch to 'debunk' negative myths. Item

Drug Delivery News

> 'Nanosponges' held in place with a hydrogel absorb toxins in MRSA infections. Story

> Study finds testosterone gels and patches safer than injections. More

> Endo to buy Par Pharma for $8B to bulk up in injectables. Item

> Celyad, formerly Cardio3, files for U.S. IPO worth up to $115 million. Article

> FDA approves pediatric version of Treximet to treat migraines. Report

Pharma Manufacturing News

> Pharmaniaga project in Saudi Arabia stalls but others move forward. More

> Janssen gets Rutgers' help in move to continuous manufacturing. Article

> FDA blesses Baxter saline plant in Spain to produce for U.S. More

> J&J donates $6M to Rutgers, which is helping Janssen move to continuous manufacturing. Story

> AstraZeneca says Sweden getting its new $285M biologics plant. Report

Pharma Asia News

> Wockhardt faces long haul on FDA travails, Business Today says. Story

> India's Zydus Cadila has 10 vaccines in development, set to launch next year. More

> India drug IP laws in spotlight again in local Fresenius Kabi-Pfizer case. Article

> Taiwan recalls batches of injectable sodium chloride made by Y.F. Chemical. Report

> Thailand faces pushback from private hospitals on cost claims. Item

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.